IGC Pharma, Inc.
IGC
$0.32
$0.000.72%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.11M | 1.33M | 1.27M | 1.24M | 1.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.11M | 1.33M | 1.27M | 1.24M | 1.18M |
| Cost of Revenue | 595.00K | 717.00K | 652.00K | 600.00K | 518.00K |
| Gross Profit | 511.00K | 610.00K | 619.00K | 636.00K | 665.00K |
| SG&A Expenses | 4.36M | 4.00M | 4.43M | 6.05M | 7.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.25M | 8.33M | 8.74M | 10.16M | 11.23M |
| Operating Income | -8.14M | -7.00M | -7.47M | -8.92M | -10.04M |
| Income Before Tax | -6.45M | -6.34M | -7.12M | -8.81M | -12.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.45 | -6.34 | -7.12 | -8.81 | -12.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.45M | -6.34M | -7.12M | -8.81M | -12.57M |
| EBIT | -8.14M | -7.00M | -7.47M | -8.92M | -10.04M |
| EBITDA | -7.57M | -6.41M | -6.85M | -8.30M | -9.41M |
| EPS Basic | -0.08 | -0.08 | -0.09 | -0.12 | -0.19 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.06 | -0.08 | -0.09 |
| EPS Diluted | -0.08 | -0.08 | -0.09 | -0.12 | -0.19 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.06 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 330.70M | 316.25M | 306.04M | 290.70M | 276.79M |
| Average Diluted Shares Outstanding | 330.70M | 316.25M | 306.04M | 290.70M | 276.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |